Literature DB >> 28067879

Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study.

E Yokohata1, Y Kuwatsuka2, H Ohashi3,4, S Terakura5, N Kawashima1, A Seto1,5, S Kurahashi1, Y Ozawa1, T Goto5, N Imahashi5, T Nishida5, K Miyao6, R Sakemura6, T Kato6, M Sawa6, A Kohno7, H Sao8, H Iida3, H Kiyoi5, T Naoe3,5, K Miyamura1, M Murata5.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28067879     DOI： 10.1038/bmt.2016.323

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  14 in total

1.  Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  Hans C Lee; Rima M Saliba; Gabriela Rondon; Julianne Chen; Yasmeen Charafeddine; L Jeffrey Medeiros; Gheath Alatrash; Borje S Andersson; Uday Popat; Partow Kebriaei; Stefan Ciurea; Betul Oran; Elizabeth Shpall; Richard Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-14       Impact factor: 5.742

2.  Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse.

Authors:  Nobuhiko Imahashi; Haruhiko Ohashi; Seitaro Terakura; Kotaro Miyao; Reona Sakemura; Tomonori Kato; Masashi Sawa; Emi Yokohata; Shingo Kurahashi; Yukiyasu Ozawa; Tetsuya Nishida; Hitoshi Kiyoi; Koichi Watamoto; Akio Kohno; Masanobu Kasai; Chiaki Kato; Hiroatsu Iida; Tomoki Naoe; Koichi Miyamura; Makoto Murata
Journal:  Ann Hematol       Date:  2015-02-15       Impact factor: 3.673

3.  The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation.

Authors:  T Lion; F Watzinger; S Preuner; H Kreyenberg; M Tilanus; R de Weger; J van Loon; L de Vries; H Cavé; C Acquaviva; M Lawler; M Crampe; A Serra; B Saglio; F Colnaghi; A Biondi; J J M van Dongen; M van der Burg; M Gonzalez; M Alcoceba; G Barbany; M Hermanson; E Roosnek; C Steward; J Harvey; F Frommlet; P Bader
Journal:  Leukemia       Date:  2012-03-07       Impact factor: 11.528

4.  Leukemic relapse in the central nervous system after allogeneic stem cell transplantation with complete remission in the bone marrow and donor-type chimerism: report of two cases.

Authors:  Haruhiko Ohashi; Chiaki Kato; Shoko Fukami; Hidehiko Saito; Motohiro Hamaguchi
Journal:  Am J Hematol       Date:  2005-06       Impact factor: 10.047

5.  Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.

Authors:  Theis Helge Terwey; Philipp Georg Hemmati; Marion Nagy; Heike Pfeifer; Nicola Gökbuget; Monika Brüggemann; Tanja Melinh Le Duc; Philipp le Coutre; Bernd Dörken; Renate Arnold
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-04       Impact factor: 5.742

6.  Chimerism status is correlated to acute graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Ying Jiang; Li-ping Wan; You-wen Qin; Xiao-rui Wang; Shi-ke Yan; Kuang-cheng Xie; Chun Wang
Journal:  Int J Hematol       Date:  2014-01-31       Impact factor: 2.490

7.  Peripheral blood cells chimerism after unrelated cord blood transplantation in children: kinetics, predictive factors and impact on post-transplant outcome.

Authors:  Elodie Elkaim; Christophe Picard; Claire Galambrun; Vincent Barlogis; Anderson Loundou; Catherine Curtillet; Claire Oudin; Isabelle Thuret; Hervé Chambost; Gérard Michel
Journal:  Br J Haematol       Date:  2014-04-29       Impact factor: 6.998

8.  Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies.

Authors:  B Horn; S Soni; S Khan; A Petrovic; N Breslin; M Cowan; G Pelle-Day; E Cooperstein; L-A Baxter-Lowe
Journal:  Bone Marrow Transplant       Date:  2008-10-27       Impact factor: 5.483

9.  Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.

Authors:  Biljana Horn; Aleksandra Petrovic; Justin Wahlstrom; Christopher C Dvorak; Denice Kong; Jimmy Hwang; Jueleah Expose-Spencer; Michael Gates; Morton J Cowan
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-31       Impact factor: 5.742

10.  Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT.

Authors:  X-Y Qin; G-X Li; Y-Z Qin; Y Wang; F-R Wang; D-H Liu; L-P Xu; H Chen; W Han; J-Z Wang; X-H Zhang; J-L Li; L-D Li; K-Y Liu; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-08-04       Impact factor: 5.483
View more
  3 in total

1.  Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation.

Authors:  Tatsunori Goto; Makoto Murata; Tetsuya Nishida; Seitaro Terakura; Sonoko Kamoshita; Yuichi Ishikawa; Yoko Ushijima; Yoshiya Adachi; Satoshi Suzuki; Katsuyoshi Kato; Akihiro Hirakawa; Satoshi Nishiwaki; Nobuhiro Nishio; Yoshiyuki Takahashi; Yoshihisa Kodera; Tadashi Matsushita; Hitoshi Kiyoi
Journal:  Stem Cells Transl Med       Date:  2020-12-14       Impact factor: 6.940

2.  Primary graft failure, but not relapse, may be identified by early chimerism following double cord blood unit transplantation.

Authors:  Rachael Hough; Andre Lopes; Pip Patrick; Nigel Russell; Kavita Raj; Eleni Tholouli; John A Snowden; Matthew Collin; Nadjet El-Mehidi; Anthony Lawrie; Laura Clifton-Hadley; Paul Veys; Charles Craddock; Stephen Mackinnon; Gordon Cook; Bronwen Shaw; David Marks
Journal:  Blood Adv       Date:  2022-04-12

3.  Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome.

Authors:  Hiroki Hosoi; Kazuo Hatanaka; Shogo Murata; Toshiki Mushino; Kodai Kuriyama; Akinori Nishikawa; Nobuyoshi Hanaoka; Shinobu Tamura; Hideki Nakakuma; Takashi Sonoki
Journal:  Hematol Rep       Date:  2018-09-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.